news
Vaccine for corona
Huge study on corona vaccine in 18-12 year olds: 90% efficacy in infection and 93% in symptom prevention
The joint study by Clalit and Harvard examined more than 94,000 vaccinated teens compared to the same number of non-vaccinated with the same demographics and medical background.
The study does not provide an accurate estimate for reduction in severe disease, due to the rarity in adolescents severely ill with the virus.
"Important and well-founded information for undecided parents"
Tags
Corona virus
Vaccine for corona
Teens
Research
Meirav Cohen
Wednesday, October 20, 2021, 00:00 Updated: 23:58
Share on Facebook
Share on WhatsApp
Share on general
Share on general
Share on Twitter
Share on Email
0 comments
Exercises for relieving back pain in seconds
Five facts about weddings
A man threatened with an ax at security guards at a hospital in Nahariya ...
The neighbor of the boy who was killed in Sderot recalls: The neighbor shouted at me -...
Gabi Patito's body found, cause of death: murder (Photo: ...
Ignition of a hayloft and tractor in Kibbutz Snir in the north 20.10.21
Plenary confrontation: MK Regev slapped MK Ben Barak: ...
Video of a power plant angle activated to produce bitcoin
Meeting of Foreign Ministers of Israel, the United States and the United Arab Emirates ...
Vigilance in Jerusalem: MKs Ben Gvir and Smutrich tour ...
The interns accepted Horowitz's outline and repeated them ...
MK Katie Sheetrit chooses shoes during a discussion in the plenum ...
In the video: Research on the corona vaccine in 18-12 year olds: 90% effectiveness in infection and 93% in preventing symptoms (Photo: Clalit Health Services)
A joint study by the Clalit Research Institute and Harvard University was published yesterday (Wednesday) in the leading medical journal New England Journal of Medicine, according to which the effectiveness of corona vaccines among 18-12 year olds is 90% in preventing infection and 93% in preventing disease with symptoms - also against Delta strain .
This is the broadest and most comprehensive study ever conducted on these age groups.
The study included vaccinators between June 8 and September 14, 2021, during the fourth wave.
The research method is similar to previous huge studies conducted by Clalit and published in the same journal.
The researchers reviewed data from 94,354 vaccinated adolescents aged 12 to 18, who were carefully matched to a control group of 94,354 unvaccinated adolescents - with identical data in terms of demographics, geography, clinical background and health behavior, associated with the risk of corona infection.
The study does not provide an accurate estimate of the effect of the vaccine on the intensity of reduction in cases of severe morbidity, as not enough information has yet been accumulated on this outcome in this age group, due to the relative rarity of severe disease in adolescents.
More on Walla!
Ministry of Health: Parents caring for a child with corona until the age of 12 are exempt from isolation
To the full article
More on Walla!
Contrary to the FDA: The EU has approved a third vaccine against Pfizer's corona from the age of 18
In the coming weeks: Pfizer will make a formal application to the FDA to vaccinate 11-5 year olds against Corona
Attack yourself: What is comprehensive insurance and when is it critical?
A teenager gets vaccinated at Clalit's vaccination complex, Petah Tikva (Photo: Reuven Castro)
Prof. Ran Blitzer, head of Clalit's innovation division: "With the outbreak of the fourth wave due to the Delta strain, the question arose whether the vaccine used in Israel also provides adequate protection against infection with this strain, as it protected against the alpha strain after the vaccination in January. This wave, evaluating the effectiveness of the vaccine in them can provide an answer to the question. "
"The results of the study show unequivocally that the vaccine is most effective in reducing Delta strain infection and preventing symptomatic disease one week after receiving two doses. And is based on parents who are undecided about vaccinating their adolescent children, "Blitzer concluded.
Pfizer will apply to the FDA for approval of an emergency vaccine against Corona for ages 11-5 (Photo: Reuven Castro)
In the background of the study, during November Pfizer is expected to submit to the FDA the request for an emergency vaccine against corona for children aged 11-5, after experiments conducted by the company found that the vaccine is effective and safe wave among this age group, as in other age groups.
On September 28, the company submitted to the regulators in the United States their experimental data from child vaccination in this age range.
Pfizer said on September 20 that the two doses of the vaccine, which is already approved for the general population over the age of 12, elicited a strong immune response in 2,268 trial participants aged 11-5 - the same as the one that occurred among 25-16 year olds.
Also, the level of safety from the vaccine was similar to that of the older age group.
Share on Facebook
Share on WhatsApp
Share on general
Share on general
Share on Twitter
Share on Email
0 comments
